- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06181721
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes (Evolution)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a single-arm, observational clinical study that will enroll a maximum of 72 participants.
Participants between the ages of 16+ years with type 1 or type 2 diabetes currently using an insulin pump or receiving basal and bolus multiple daily injections (MDI), with an A1C between 7.5-11.0% at screening, will be recruited for the study.
Two participant groups will be recruited and will participate in up to 4 Phases:
- Group A (Participants with type 1 diabetes) will participate in Phase 1, Phase 2, Phase 3, and Phase 4
- Group B (Participants with type 2 diabetes) will participate in Phase 1, and Phase 4
Phase 1 (Group A and B) will include:
• 14 days of Standard Therapy while using a blinded Dexcom G6 CGM in an outpatient setting
Phase 2 (Group A only) will include:
• 48 hours of using build 1b.x of the Omnipod 5 System in Manual Mode in an outpatient setting
Phase 3 (Group A only) will include:
• 3 day/2 night supervised hotel stay using build 1b.x of the Omnipod 5 System in Automated Mode while also participating in meal and exercise challenges at a defined target glucose setting of 5.6 mmol/L (100 mg/dL). During the first 24 hours, participants will be instructed to not bolus for meals. For the following 24 hours, participants will be instructed to bolus for meals. At least 2 meals each day must contain at least 60 grams of carbohydrates. In addition, each day participants will take part in 45 minutes of exercise.
Phase 4 (Group A and B) will include:
• A total of 6 weeks using the Omnipod 5 System in Automated Mode in an outpatient setting at a defined target glucose setting of 5.6 mmol/L (100 mg/dL). During weeks 1-3, participants will be instructed to bolus for meals. During weeks 4-6, participants will be instructed to not bolus for meals.
After completion of a minimum of 10 participants for Group A, Phase 3, the data will be analysed and must meet prespecified criteria for Group A to proceed to Phase 4 and Group B to proceed to Phase 1 followed by Phase 4.
If the prespecified criteria are not met, software changes will be made and Group A, Phase 3 may be repeated either with the same participants or additional participants that meet the study criteria. Iterations of Group A, Phase 3 may continue until prespecified criteria are met.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Christchurch, New Zealand, 8140
- University of Otago
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria-
Participants must meet all the following criteria to be included in the study:
- Age at time of consent 16+ years
- Individuals must be diagnosed with type 1 diabetes based on investigator's clinical judgment for at least 1 year. Individuals diagnosed with type 2 diabetes must be on basal and bolus insulin therapy, with no specified duration.
- A1C between 7.5-11.0% at screening
- Currently using U-100 rapid-acting insulin analogs with insulin pump or receiving multiple daily injections suitable for conversion to pump therapy for at least 3 months prior to study start
- Willing to use a Dexcom G6 CGM for the duration of the study
- Willing to use the Omnipod® 5 Automated Insulin Delivery System during the study
- Willing to perform all fingerstick BG testing with their personal blood glucose meter at the frequency specified in the study protocol or per investigator discretion
- Willing to participate in at least 45 minutes of exercise and meal challenges during the 3 day hotel stay (Group A only)
- Willing to use carbohydrate counting for determination of meal boluses
- Willing and able to sign the Informed Consent Form (ICF) and/or has a parent/guardian willing and able to sign the ICF.
Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from the study:
- Any medical condition, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal failure, eating disorders, or other conditions which in the opinion of the investigator, would put the participant at an unacceptable safety risk
- Blood disorder or dyscrasia within 3 months prior to screening, including the use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1C.
- History of severe hypoglycemia within the past 6 months
- History of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome in the past 6 months, unrelated to an intercurrent illness or infusion set failure
- History of moderate to severe preproliferative or proliferative retinopathy based on screening within the last 12 months.
- Planning to start a non-insulin anti-diabetic medication during the study. If on non-insulin medication, dose must be stable in the previous 30 days.
- Planning to start a weight-loss agent during the study. If on a weight-loss medication, dose must be stable in the previous 30 days.
- Currently on a low carbohydrate diet of < 60 grams of carbohydrates per day
- Pregnant, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilisation such as tubal ligation or hysterectomy, or vasectomised partner)
- Dermatological conditions at the proposed sensor/pump wear sites that in the investigator's opinion could preclude ability to wear the Pod and/or the Dexcom sensor
- Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12 months.
- Currently on systemic steroids or intends to receive systemic steroid treatment in the next 6 months, including stable treatment for adrenal insufficiency. Inhaled, ophthalmic, topical, joint injection, and other locally applied steroids are allowed.
- Currently participating in another clinical study using an investigational drug or device
- Recent (within the preceding 30 days) participation in a clinical study using an investigational drug
- Unable to follow the clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A with Type 1 Diabetes
Participants with Type 1 Diabetes
|
The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
|
Experimental: Group B with Type 2 Diabetes
Participants with Type 2 Diabetes
|
The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of time in hypoglycemic range (defined as < 3.9 mmol/L (<70 mg/dL))
Time Frame: At the end of Phase 3 and Phase 4 to compare to baseline values
|
Glucose metric from CGM
|
At the end of Phase 3 and Phase 4 to compare to baseline values
|
Percentage of time in hyperglycemic range (defined as > 13.9 mmol/L (>250 mg/dL))
Time Frame: measured during the 9 week study phase
|
Glucose metric from CGM
|
measured during the 9 week study phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean glucose value of all participants
Time Frame: Measured during the 9 week study phase
|
Glucose metric from study provided continuous glucose monitor (CGM)
|
Measured during the 9 week study phase
|
Percentage of time < 3.0 mmol/L (<54 mg/dL)
Time Frame: Measured during the 9 week study phase
|
Glucose metric from CGM
|
Measured during the 9 week study phase
|
Percentage of time > 10.0 mmol/L (>180 mg/dL)
Time Frame: Measured during the 9 week study phase
|
Glucose metric from CGM
|
Measured during the 9 week study phase
|
Percentage of time > 16.7 mmol/L (>300 mg/dL)
Time Frame: Measured during the 9 week study phase
|
Glucose metric from CGM
|
Measured during the 9 week study phase
|
Percentage of time between 3.9-10.0 mmol/L (70-180 mg/dL)
Time Frame: Measured during the 9 week study phase
|
Glucose metric from CGM
|
Measured during the 9 week study phase
|
Standard deviation and coefficient of variation
Time Frame: Measured during the 9 week study phase
|
Glucose metric from CGM measured glucose variability with the coefficient of variation (CV)
|
Measured during the 9 week study phase
|
Average total daily insulin (TDI)
Time Frame: Measured during the 9 week study phase
|
measure of insulin
|
Measured during the 9 week study phase
|
Average TDI/kg
Time Frame: Measured during the 9 week study phase
|
measure of insulin
|
Measured during the 9 week study phase
|
Average number of manual boluses/day
Time Frame: Measured during the 9 week study phase
|
count of average number of insulin boluses
|
Measured during the 9 week study phase
|
Average dose of insulin delivered by manual bolus/day
Time Frame: Measured during the 9 week study phase
|
measure of insulin
|
Measured during the 9 week study phase
|
Average number of hypoglycemic treatments when CGM is less than 3.9mmol/L
Time Frame: Measured during the 9 week study phase
|
Glucose metric from CGM
|
Measured during the 9 week study phase
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EVOLUTION
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Omnipod 5 Automated Glucose Control System
-
Insulet CorporationJaeb Center for Health ResearchCompleted
-
Insulet CorporationCompletedType 1 DiabetesUnited States
-
Insulet CorporationCompletedType 1 Diabetes MellitusUnited States
-
Insulet CorporationCompleted
-
Insulet CorporationCompleted
-
Insulet CorporationCompletedType 2 Diabetes MellitusUnited States
-
Insulet CorporationActive, not recruiting
-
Insulet CorporationActive, not recruitingDiabetes Mellitus, Type 1Belgium, France, United Kingdom
-
Insulet CorporationCompleted
-
Emory UniversityJaeb Center for Health Research; Insulet CorporationCompletedDiabetes MellitusUnited States